2024 ESMO Conference reveals promising efficacy data for ivonescimab in first-line metastatic colorectal cancer treatment; combination superior to standard treatments with manageable safety.

Akeso revealed promising efficacy data for its PD-1/VEGF bispecific antibody, ivonescimab, at the 2024 ESMO Conference. The findings indicate that ivonescimab, both alone and with ligufalimab and FOLFOXIRI, exhibits strong anti-tumor activity for first-line treatment of metastatic colorectal cancer (MSS/pMMR). The combination showed superior efficacy compared to standard treatments, with manageable safety profiles, supporting further research.

September 15, 2024
3 Articles

Further Reading